Skip to main content
Internal view of patient's torso demonstrating targeted accuracy of TheraSphere Y-90 Glass Microspheres in liver.

TheraSphere™ Y-90 Glass Microspheres

Clinical data details

Hepatocellular Carcinoma (HCC)

Explore clinical data at different HCC stages

Metastatic Colorectal Cancer (mCRC)*

Explore clinical data for mCRC

Caution: In the US, TheraSphere is under an investigational device exemption to treat patients with metastatic colorectal cancer. The safety and effectiveness of this treatment have not been established.

Y-90 vs. other LRTs

Explore clinical data for Y-90 vs. other locoregional therapy (LRT) options


*TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child- Pugh Score A cirrhosis, well compensated liver function, no macrovascular invasion, and good performance status.

**The loading of doxuribicin to LC Beads is outside of the indication for use in the USA.